Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

@article{Petrylak1999PhaseIT,
  title={Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.},
  author={Daniel Peter Petrylak and Robert B Macarthur and Julie O'Connor and G. B. Shelton and Timothy Judge and Joan Z. Balog and Charles H Pfaff and E Bagiella and Daniel Heitjan and Robert Fine and N. Zuech and Ihor S. Sawczuk and Mitchell C. Benson and Carl A. Olsson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 3},
  pages={958-67}
}
PURPOSE To evaluate the toxicity, efficacy, and pharmacokinetics of docetaxel when combined with oral estramustine and dexamethasone in a phase I study in patients with progressive metastatic androgen-independent prostate cancer. PATIENTS AND METHODS Thirty-four men were stratified into minimally pretreated (MPT) and extensively pretreated (EPT) groups. Estramustine 280 mg PO tid was administered 1 hour before or 2 hours after meals on days 1 through 5, with escalated doses of docetaxel from… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Similar Papers

Loading similar papers…